Improving Maintenance Following Very Low Calorie Diet: The Sustain Lost Weight (SLW) Intervention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01222988
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : January 17, 2013
Information provided by:
Mayo Clinic

Brief Summary:

Obtain a preliminary assessment of the feasibility and acceptability of delivering the sustained lost weight (SLW) intervention in a real-world clinical setting for patients who have completed a 21-week very low calorie diet (VLCD).

Hypothesis: Intervention will be feasible to implement as evidenced by the ability to recruit and retain participants and acceptable to participants as evidenced by self-report of satisfaction with the program and adoption of weight maintenance behaviors.

Secondary Aim: Obtain a preliminary assessment of the effectiveness of the sustained lost weight (SLW) intervention for patients who have completed 21 weeks of a very low calorie diet (VLCD).

Hypothesis: Greater than 75% of participants who receive this novel approach, where maintenance behaviors are individualized based on resting metabolic rate and a physical activity factor, will regain greater or equal to 10 kg. at week 52 follow-up.

Condition or disease Intervention/treatment Phase
Obesity Dietary Supplement: Optifast Products Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Study Start Date : October 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Arm Intervention/treatment
very low calorie diet program Dietary Supplement: Optifast Products
Optional Optifast products offered once every other week X 6 months; then monthly.
Other Name: Optifast Dietary Supplements

Primary Outcome Measures :
  1. Treatment Feasibility [ Time Frame: 52 weeks ]
    Treatment will be considered feasible if greater than 50 % of participants attend a minimum of 17 of 20 sessions. The treatment will be considered acceptable for further study if greater than 50% of participants rate the maintenance program with a mean score of 6 or higher.

Secondary Outcome Measures :
  1. Weight Gain Analysis [ Time Frame: 52 weeks ]
    Weight regain from week 1 to 52 will be analyzed. Patients who discontinue the study or are lost to follow-up will be assumed to have gained more than 10 kg at 12 months.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed fast and transition period of the OPTIFAST® program
  • Be able to participate fully in all aspects of the study
  • Willing to refrain from participating in additional weight loss interventions for the duration of the study
  • Willing to provide written informed consent.

Exclusion Criteria:

  • Myocardial infarction within 6 months
  • Unstable angina
  • Stroke
  • Chronic steroid use
  • Active peptic ulcer disease
  • Advanced cirrhosis
  • Active hepatitis
  • Advanced renal disease
  • Active thrombophlebitis
  • Recent skeletal fractures
  • Use of lithium
  • Pancreatitis
  • Pregnancy
  • Type 1 diabetes mellitus
  • History of diabetic ketoacidosis
  • Active bulimia nervosa
  • Severe depression
  • Psychosis
  • Substance abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01222988

United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Gretchen Ames, Ph.D. Mayo Clinic

Responsible Party: Gretchen E. Ames, Ph.D., Mayo Clinic Identifier: NCT01222988     History of Changes
Other Study ID Numbers: 10-002960
First Posted: October 18, 2010    Key Record Dates
Last Update Posted: January 17, 2013
Last Verified: January 2013